MedTrace Logo

Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients

NCT00235560 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-02-29

No results posted yet for this study

Summary

These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

Conditions

Interventions

DRUG

rapamycin

sirolimus

Sponsors & Collaborators

  • French Innovative Leukemia Organisation

    collaborator OTHER

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • RECHER Christian · University Hospital, Toulouse

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00235560 on ClinicalTrials.gov